Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.

Bronchopulmonary dysplasia is a leading cause of mortality and morbidity in preterm infants despite improved treatment modalities. Pentoxifylline, a phosphodiesterase inhibitor, inhibits multiple processes that lead to neonatal hyperoxic lung injury, including inflammation, coagulation, and edema. Using a preterm rat model, we investigated the effects of pentoxifylline on hyperoxia-induced lung injury and survival. Preterm rat pups were exposed to 100% oxygen and injected subcutaneously with 0.9% saline or 75 mg/kg pentoxifylline twice a day. On day 10, lung tissue was harvested for histology, fibrin deposition, and mRNA expression, and bronchoalveolar lavage fluid was collected for total protein concentration. Pentoxifylline treatment increased mean survival by 3 days (P = 0.0018) and reduced fibrin deposition by 66% (P < 0.001) in lung homogenates compared with untreated hyperoxia-exposed controls. Monocyte chemoattractant protein-1 expression in lung homogenates was decreased, but the expressions of TNF-alpha, IL-6, matrix metalloproteinase-12, tissue factor, and plasminogen activator inhibitor-1 were similar in both groups. Total protein concentration in bronchoalveolar lavage fluid was decreased by 33% (P = 0.029) in the pentoxifylline group. Pentoxifylline treatment attenuates alveolar fibrin deposition and prolongs survival in preterm rat pups with neonatal hyperoxic lung injury, probably by reducing capillary-alveolar protein leakage.

[1]  S. Kotecha.  Cytokines in chronic lung disease of prematurity , 1996, European Journal of Pediatrics.

[2]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.

[3]  G. Óskarsson.  Coronary flow and flow reserve in children , 2004, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[4]  F. Walther,et al.  Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. , 2004, Free radical biology & medicine.

[5]  R. Auten,et al.  Antimacrophage chemokine treatment prevents neutrophil and macrophage influx in hyperoxia-exposed newborn rat lung. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[6]  C. Gravholt,et al.  Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[7]  M. Zembala,et al.  Pentoxyfylline in and prevention and treatment of chronic lung disease , 2004, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[8]  W. Loomis,et al.  Pentoxifylline reduces acute lung injury in chronic endotoxemia. , 2003, The Journal of surgical research.

[9]  M. Carraway,et al.  Blockade of tissue factor: treatment for organ injury in established sepsis. , 2003, American journal of respiratory and critical care medicine.

[10]  E. Bancalari,et al.  Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. , 2003, Seminars in neonatology : SN.

[11]  V. Bhandari,et al.  Release of cytokines and apoptosis in fetal rat Type II pneumocytes exposed to hyperoxia and nitric oxide: modulatory effects of dexamethasone and pentoxifylline. , 2002, Cytokine.

[12]  L. Wright,et al.  NICHD Neonatal Research Network , 2002 .

[13]  N. Willich,et al.  Modulation of radiation-induced tumour necrosis factor α (TNF-α) expression in the lung tissue by pentoxifylline , 2002 .

[14]  张锺儒,et al.  对急性哮喘加剧的成年患者两种不同教育干预的评价[英]／Co^^té J…∥Am J Respir Crit Care Med , 2002 .

[15]  N. Willich,et al.  Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[17]  C R Bauer,et al.  Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. , 2001, Pediatrics.

[18]  F. Walther,et al.  Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. , 2000, The European respiratory journal.

[19]  T. Krakauer.  Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells. , 2000, Immunopharmacology.

[20]  A. Jobe.  The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.

[21]  M. Yen,et al.  Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia. , 1999, European journal of pharmacology.

[22]  M. Zembala,et al.  Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. , 1999, Critical care medicine.

[23]  A. Jobe,et al.  Mechanisms initiating lung injury in the preterm. , 1998, Early human development.

[24]  D. Breuillé,et al.  Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[25]  R. Todd,et al.  Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. , 1998, Journal of immunology.

[26]  J. Wispé,et al.  Functional and pathological effects of prolonged hyperoxia in neonatal mice. , 1998, American Journal of Physiology.

[27]  H. Rayburn,et al.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. , 1998, The Journal of clinical investigation.

[28]  J. Tyson,et al.  Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. , 1998, American journal of obstetrics and gynecology.

[29]  L. Frank,et al.  Prenatal dexamethasone administration to premature rats exposed to prolonged hyperoxia: a new rat model of pulmonary fibrosis (bronchopulmonary dysplasia). , 1997, The Journal of pediatrics.

[30]  D. Belin,et al.  Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. , 1996, The Journal of clinical investigation.

[31]  M. Silverman,et al.  Increase in Interleukin (IL)-1β and IL-6 in Bronchoalveolar Lavage Fluid Obtained from Infants with Chronic Lung Disease of Prematurity , 1996, Pediatric Research.

[32]  Jeffrey F. Young,et al.  Changes in Structure, Mechanics, and Insulin-Like Growth Factor-Related Gene Expression in the Lungs of Newborn Rats Exposed to Air or 60% Oxygen , 1996, Pediatric Research.

[33]  M. Silverman,et al.  Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease. , 1995, Archives of disease in childhood. Fetal and neonatal edition.

[34]  J. Sznajder,et al.  Pentoxifylline does not protect against hyperoxic lung injury in rats. , 1994, The European respiratory journal.

[35]  T. van der Poll,et al.  Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. , 1994, The Journal of clinical investigation.

[36]  W. Seeger,et al.  Proteolytic cleavage of fibrinogen: amplification of its surfactant inhibitory capacity. , 1993, American journal of respiratory cell and molecular biology.

[37]  T. van der Poll,et al.  Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. , 1993, Journal of immunology.

[38]  M. Thiel,et al.  Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. , 1991, Biochemical and biophysical research communications.

[39]  T. Martin,et al.  Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. , 1991, The American journal of physiology.

[40]  T. Raffin,et al.  Pentoxifylline does not attenuate acute lung injury in the absence of granulocytes. , 1991, Journal of applied physiology.

[41]  J D Horbar,et al.  Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. , 1991, Pediatrics.

[42]  T. Martin,et al.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. , 1989, The Journal of clinical investigation.

[43]  J. Weil,et al.  Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. , 1988, The American review of respiratory disease.

[44]  T. Raffin,et al.  Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. , 1988, The American review of respiratory disease.

[45]  W. J. Novick,et al.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline , 1988, Infection and immunity.

[46]  S. Clissold,et al.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. , 1987, Drugs.

[47]  E. Haber,et al.  Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. , 1983, Science.

[48]  J. Bucher,et al.  Oxygen-Induced Alterations in Lung Vascular Development in the Newborn Rat , 1983, Pediatric Research.

[49]  D. Strandness,et al.  Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. , 1982, American heart journal.

[50]  S. Ludwin,et al.  Oxygen toxicity in the newborn. The effect of prolonged 100 per cent O2 exposure on the lungs of newborn mice. , 1975, Laboratory investigation; a journal of technical methods and pathology.

[51]  P. Dunn.  Oxygen toxicity in the newborn , 1974 .